Replies to post #167549 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I apologize to all Germans for misspelling Auf Wiedersehen. Adeeose moo-nachos!

[hankmanhub]

7. Nevertheless, imo, Germany clearly tinkered with the manufacturing process. At one point, they had 90 employees working on the project. Pretty astounding when their enrollment goal was 87.

What would be the status of the resultant product after the Fraunhofer "tinkering" with DCVAX-L? Would this belong to NWBO or to Fraunhofer. If the latter, would Fraunhofer have to pay a royalty to NWBO for its use?

I realize there has been much discussion, but I have not followed it all very closely. So did the latter part of the PIII actually use the Fraunhofer improved version of DCVAX-L? Has there been any consensus on that or any ongoing dispute on that?

[CaptainObvious]

Thumbs up, flipper

[eagle8]

Thank you flipper44.

GLTU

[Lykiri]

I'm apparently becoming a rarer long that believes PFS probably succeeded.

Flipper44,

you can add me to that group!

And thank you for the information about CTL response in the blood after DC injection.

"Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment."

Linda M. Liau, Robert M. Prins, Sylvia M. Kiertscher, Sylvia K. Odesa, Thomas J. Kremen, Adrian J. Giovannone, Jia-Wei Lin, Dennis J. Chute, Paul S. Mischel, Timothy F. Cloughesy and Michael D. Roth

http://clincancerres.aacrjournals.org/content/11/15/5515

Whereas the patients who developed systemic antitumor cytotoxicity had significantly longer survival than those who did not (P = 0.04), this survival difference also correlated with the presence or absence of tumor progression at the time of dendritic cell vaccination.
The development of a positive CTL response was negatively associated with active progressive disease (as measured by brain MRI). 100% (six of six) of patients who generated positive CTL responses had stable/minimal residual disease burden (stable gross residual disease or no measurable residual disease) at the time of dendritic cell vaccination. Conversely, for the five patients who were experiencing active tumor progression at the time of vaccination, none (zero of five) developed statistically significant cell-mediated CTL responses. These data suggest that glioblastoma multiforme patients with active tumor progression/recurrence may have an impaired ability to mount cellular antitumor immune responses, a finding that has been observed previously (33, 34).

[Lorie3168]

This is a story that could play out in a novel if the vaccine gains approval. So many twists and turns. This can NOT be made up! The brilliant minds involved in this. Quite astounding!! Thank you for this most interesting post.